BEDFORD, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. ( ANIK), a global leader in the osteoarthritis (”OA”) pain management and regene
Anika Therapeutics (ANIK) granted stock options to two new non-executive employees. The options cover 5,000 shares at an exercise price of $14.46 each.
On May 12, 2025, Anika Therapeutics (ANIK) received an update from Barrington Research regarding its stock evaluation. Michael Petusky, an analyst at Barrington
Investment firm Barrington has adjusted its price target for Anika Therapeutics (ANIK), reducing it from $20 to $19, while maintaining an Outperform rating. Des
Release Date: May 09, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Anika Therapeutic
Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NANIK.OQ - Anika Therapeutics IncQ1 2025 Anika Therapeutics Inc Earnings CallMay 09, 2025 / 12:
Redburn Atlantic has upgraded MongoDB (MDB) from a Sell to a Neutral rating, with the price target adjusted to $170 from a previous $180. The decision follows t
Analyst Anderson Schock from B. Riley has initiated coverage on Anika Therapeutics (ANIK) with a "Buy" recommendation and set a price target of $21. Anika Thera
Shares of Intel Corporation INTC rose sharply in today's pre-market trading after the company announced a new chief executive officer.
The company said its boa...
Q4 Revenue: $30.6 million, up 1% year-over-year.Full Year Revenue: $119.9 million, a decrease of 1% compared to 2023.Commercial Channel Revenue: Up 25% in Q4 a
Mar 12, 2025 / 09:00PM GMTOperator Good evening, Good morning, ladies and gentlemen, and welcome to Anika's fourth quarter and year-end earnings conference call
Full Year 2024 results in line with guidance with Commercial Channel revenue up 17% Strong International OA Pain Management and greater than 40% sequential